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A Randomized Clinical Trial to
Evaluate the Safety and Efficacy of a
Percutaneous Left Ventricular Assist Device
Versus Intra-Aortic Balloon Pumping for Treatment
of Cardiogenic Shock Caused by Myocardial Infarction
Melchior Seyfarth, MD,*† Dirk Sibbing, MD,* Iris Bauer, MS,* Georg Fröhlich, MD,†
Lorenz Bott-Flügel, MD,† Robert Byrne, MB, MRCPI,* Josef Dirschinger, MD,†
Adnan Kastrati, MD,* Albert Schömig, MD*†
Munich, Germany
Objectives The aim of this study was to test whether the left ventricular assist device (LVAD) Impella LP2.5 (Abiomed
Europe GmbH, Aachen, Germany) provides superior hemodynamic support compared with the intra-aortic
balloon pump (IABP).
Background Cardiogenic shock caused by left ventricular failure is associated with high mortality in patients with acute
myocardial infarction (AMI). An LVAD may help to bridge patients to recovery from left ventricular failure.
Methods In a prospective, randomized study, 26 patients with cardiogenic shock were studied. The primary end point
was the change of the cardiac index (CI) from baseline to 30 min after implantation. Secondary end points
included lactic acidosis, hemolysis, and mortality after 30 days.
Results In 25 patients the allocated device (n  13 IABP, n  12 Impella LP2.5) could be safely placed. One pa-
tient died before implantation. The CI after 30 min of support was significantly increased in patients with
the Impella LP2.5 compared with patients with IABP (Impella: CI  0.49  0.46 l/min/m2; IABP: CI 
0.11  0.31 l/min/m2; p  0.02). Overall 30-day mortality was 46% in both groups.
Conclusions In patients presenting with cardiogenic shock caused by AMI, the use of a percutaneously placed LVAD
(Impella LP 2.5) is feasible and safe, and provides superior hemodynamic support compared with standard
treatment using an intra-aortic balloon pump. (Efficacy Study of LV Assist Device to Treat Patients With
Cardiogenic Shock [ISAR-SHOCK]; NCT00417378) (J Am Coll Cardiol 2008;52:1584–8) © 2008 by the
American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2008.05.065(
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Sardiogenic shock (CS) affects about 6% to 8% of patients
ith acute myocardial infarction (AMI), and remains asso-
iated with a mortality rate of 40% to 50% despite a high
ate of early revascularization and use of intra-aortic balloon
ump (IABP) counterpulsation (1). Because of limited
emodynamic benefits inherent in IABP therapy, new
echnological developments such as left ventricular assist
evices (LVAD) have focused on improved hemodynamic
upport of the failing ventricle to bridge patients to recovery
rom the *Deutsches Herzzentrum München and †1. Medizinische Klinik rechts der
sar, Technische Universität, Munich, Germany.
Supported by Abiomed Europe GmbH, Germany. Dr. Seyfarth received lecture
ees from Abiomed. Presented in part as a Late-Breaking Clinical Trial at the
merican College of Cardiology 2007 Annual Meeting, New Orleans, Louisiana.2
Manuscript received January 15, 2008; revised manuscript received April 22, 2008,
ccepted May 27, 2008.2). Recently developed LVADs either have been limited by
ignificant complication rates (3) or have required cardiac
urgery for implantation (2). The Impella LP2.5 (Abiomed
urope GmbH, Aachen, Germany) is a catheter-based,
mpeller-driven, axial-flow pump with a maximal flow of 2.5
/min from the left ventricle to the ascending aorta and can
e implanted via a percutaneous approach (4,5). The ISAR-
HOCK (Impella LP2.5 vs. IABP in Cardiogenic
HOCK) trial is the first study to test this technology in a
andomized manner and should test the hypothesis that the
mpella LP2.5 provides superior hemodynamic support
ompared with IABP in patients with CS caused by AMI.
ethods
tudy design. The study was conducted as a prospective,
-center, randomized trial. All patients with AMI and a
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November 4, 2008:1584–8 LVAD Versus IABP in Cardiogenic Shockompromised hemodynamic state received positive inotropic
rugs as needed. After initial assessment of hemodynamics,
ligible patients were randomly assigned to either treatment
ith IABP or Impella LP2.5. Patients were immediately
ransferred to the catheterization laboratory for coronary
ngiography. The assigned device was implanted after
evascularization therapy and following the measurement of
aseline hemodynamic parameters. Thirty minutes later, a
ubsequent hemodynamic measurement was undertaken to
alculate the primary end point of the study with maximal
upport of both devices. Between both measurements, the
oses of vasopressors remained unchanged by protocol.
hereafter no further regulation by protocol was mandated.
s long as the assigned device was implanted, heparin was
iven intravenously adjusted to a partial thromboplastin
ime of 60 to 80 s. No additional heparin was used for
urging the Impella LP2.5 device.
The study protocol was approved by the institutional
thics committees. Exemption from informed consent was
pecifically approved by the ethical board for patients who
ere unable to give informed consent following the Na-
ional Institutes of Health/Food and Drug Administration
uidelines for emergency research (21 CFR 50.24).
Eligible participants for this study were patients with
MI48 h and CS; CS was defined using both clinical and
emodynamic criteria as previously described in the
HOCK trial (6). Please see the Online Appendix for
etails of the inclusion and exclusion criteria of the study.
ercutaneous transvalvular LVAD. The Impella LP2.5
evice, a catheter-based miniaturized rotary blood pump,
as inserted via a 13-F sheath in the femoral artery and
laced retrogradely through the aortic valve. The microaxial
ump continuously aspirates blood from the left ventricle
nd expels it to the ascending aorta with a maximal flow of
.5 l/min (5).
tatistical analysis. The primary end point of the study
as the hemodynamic improvement at 30 min after implan-
ation defined as the change in cardiac index (CI) from
aseline. Secondary end points of the study were hemody-
amic and metabolic parameters; all-cause mortality at 30
ays; device-related complications including hemolysis, ma-
or bleeding, cerebrovascular events, limb ischemia, and
ultiple-organ dysfunction scores at 30 days using Multiple
rgan Dysfunction Score (MODS) and Sepsis-related Or-
an Failure Assessment (SOFA) criteria. Cardiac power
ndex (CPI) was calculated as: CI  mean arterial pressure
MAP)  0.0022 (7). With a sample size of 26 patients, we
chieved 80% power to detect a significant enhancement of
I from0.15 l/min in patients with IABP to0.50 l/min
n patients with Impella ( level of 0.05). For further details
f the statistical analysis, please see the Online Appendix.
esults
aseline characteristics. We included 26 patients in this
nalysis. There were no significant differences between the ntudy groups with respect to clin-
cal characteristics (Table 1) and
aseline hemodynamics (Table
). In keeping with the inclusion
riteria, the CI of the study pa-
ients was low (1.7  0.5 l/min/
2) and MAP was reduced (75
16 mm Hg). On admission,
2% (IABP) and 84% (Impella
P2.5) received vasopressor
herapy (p  0.83).
tudy intervention. The percu-
aneous coronary intervention
as performed in all except 2
atients (1 in each group) (Table
) and was successful in more
han 90% in both groups. All
evices were implanted after per-
utaneous coronary intervention
ia the access site. One patient assigned to Impella LP2.5
ied after enrollment before implantation. The time re-
uired to implant the device was longer in the Impella group
Impella: 22  9 min; IABP: 14  8 min; p  0.40).
emodynamic effects. The primary end point of the study
CI) was achieved in 25 patients. The patient who died
efore implantation was additionally included in the analysis
y assuming a null effect (Table 2). The CI was signifi-
antly greater in Impella patients (CI  0.49  0.46
/min/m2) than in patients with IABP (CI  0.11  0.31
/min/m2; p  0.02). The MAP increased in patients with
mpella LP2.5 by 9.0  14.0 mm Hg versus 1.2  16.2
m Hg in the IABP group (p  0.09). The greatest
ifference was observed in diastolic arterial pressure, which
ncreased by 9.2 12.1 mm Hg under Impella support, and
as reduced by8.0 13.1 mm Hg in patients with IABP
p  0.002) (Table 2).
The CI improved in both groups during the next hours:
fter 4 h, CI was 2.23 0.58 l/min/m2 in the Impella group
nd 2.25  0.92 l/min/m2 in the IABP group. After 30 h,
I was 2.51 0.53 l/min/m2 in the Impella group and 2.40
.67 l/min/m2 in the IABP group. Figure 1A shows the
PI, which also gradually recovered in the subsequent 30 h
n both groups. Because the overall CPI was only slightly
igher in Impella patients at the subsequent time points, the
ndogenous cardiac output of the left ventricle was signifi-
antly lower at all time points in Impella patients because of
he additional work of the LVAD (Fig. 1A).
Serum lactate was lower in patients treated with Impella
uring the first 48 h at all time points (Fig. 1B). The area
nder the curve for serum lactate was 123 87 h·mmol/l in
atients with Impella compared with 180  147 h·mmol/l
n patients with IABP (p  0.12). During the first 24 h,
rine output was 110 (76 to 197) ml/h in patients assigned
o Impella versus 117 (95 to 223) ml/h in patients assigned
o IABP. The overall dose of the vasopressor agent epi-
Abbreviations
and Acronyms
AMI  acute myocardial
infarction
CI  cardiac index
CPI  cardiac power index
CS  cardiogenic shock
IABP  intra-aortic balloon
pump
LVAD  left ventricular
assist device
MAP  mean arterial
pressure
MODS  Multiple Organ
Dysfunction Score
SOFA  Sepsis-related
Organ Failure Assessmentephrine was similar in both groups during the first 24 h
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LVAD Versus IABP in Cardiogenic Shock November 4, 2008:1584–8Impella: 7.1 [0.8 to 13.5] mg/kg; IABP: 4.2 [1.0 to 13.5]
g/kg; p  0.63) as well as the median vasopressor support
ime (Impella: 46 [7.4 to 67.0] h; IABP: 46 [19.5 to 83.8]
). However, the mechanical ventilation support time was
horter in the Impella group than in the IABP group, 48
6.7 to 147.8) h versus 98 (21.3 to 167.5) h, respectively
p  0.15).
linical outcomes. The median duration of support was
5 (6.0 to 41.0) h in patients with Impella and 23 (14.1
o 34.1) h in patients with IABP. Excluding the patients
ho died during support (3 patients in each group), the
edian duration of support with Impella was 38 (21.8 to
Baseline Patient Characteristics
Table 1 Baseline Patient Characteristics
Age, median [IQR], yrs
Male gender, n (%)
Arterial hypertension, n (%)
Diabetes mellitus, n (%)
Smoking, n (%)
Hypercholesterolemia, n (%)
LVEF, median [IQR], %
Multivessel disease, n (%)
Peak creatine kinase, median [IQR], U/l
Anterior myocardial infarction, n (%)
Time from AMI to randomization, median [IQR], h
Mechanical ventilation at admission, n (%)
CPR, VT, or VF before randomization, n (%)
pH at admission, median [IQR]
Urine output at admission, median [IQR], ml/h
PCI as revascularization, n (%)
CABG as revascularization, n (%)
TIMI flow grade before PCI
0/1
2/3
TIMI flow grade after PCI
3
AMI  acute myocardial infarction; CABG  coronary artery bypass gra
IQR  interquartile range; LVEF  left ventricular ejection fraction, d
assigned device; PCI percutaneous coronary intervention; STEMI S
Infarction; VF  ventricular fibrillation; VT  ventricular tachycardia.
emodynamic Values Before and After Device Implantation
Table 2 Hemodynamic Values Before and After Device Implanta
Impella Before
(n  13)
IABP Befo
(n  13)
CI (l/min/m2) 1.71 0.45 1.73 0.
CO (l/min) 3.16 0.77 3.46 1.
Mean AP (mm Hg) 78 16 72 17
Systolic AP (mm Hg) 106 22 101 23
Diastolic AP (mm Hg) 64 15 58 14
Heart rate (beats/min) 95 24 97 24
PCWP (mm Hg) 22 8 22 7
RAP (mm Hg) 13 7 12 6
Mean PAP (mm Hg) 28 8 28 9
SVR (dyn·s·cm5) 1,617 385 1,546 76
alues are mean  SD; p values are for independent comparisons of values for Impella after and
AP  arterial pressure; CI  cardiac index; CO  cardiac output; IABP  intra-aortic balloon pump; PAP
ressure; SVR  systemic vascular resistance.1.1) h versus 23 (14.8 to 31.1) h with IABP (p  0.26).
uring support we observed no device-related technical
ailure, major bleeding, or ischemia. There was 1 case of
cute limb ischemia requiring surgery after device explan-
ation in a patient assigned to Impella. Hemolysis was
ssessed by measurements of free hemoglobin, which was
ignificantly higher in Impella patients in the first 24 h
Fig. 1C). During intensive care treatment, more packed red
lood cells and fresh-frozen plasma were administered to
mpella patients (red blood cells: Impella 2.6  2.7 U vs.
ABP 1.2  1.9 U, p  0.18; and fresh-frozen plasma:
mpella 1.8  2.5 U vs. IABP: 1.0  1.7 U, p  0.39).
pella LP2.5 (n  13) IABP (n  13)
65 [57–71] 67 [55–80]
8 (62) 11 (85)
7 (54) 9 (69)
5 (39) 3 (23)
8 (62) 7 (54)
8 (62) 7 (54)
27 [20–39] 28 [23–44]
9 (69) 10 (77)
719 [295–8,535] 4,150 [2,275–9,310]
7 (54) 8 (62)
4.5 [3.8–13.2] 5.0 [3.3–13.0]
12 (92) 12 (92)
11 (85) 9 (69)
.31 [7.21–7.42] 7.24 [7.18–7.37]
52 [28–90] 35 [19–67]
12 (92) 12 (92)
0 1 (8)
7 (54) 8 (62)
6 (46) 5 (38)
12 (100) 12 (92)
 cardiopulmonary resuscitation; IABP  intra-aortic balloon pump;
ned before percutaneous coronary intervention and implantation of
nt elevationmyocardial infarction; TIMI Thrombolysis In Myocardial
Impella After
(n  13)
IABP After
(n  13) p Value
2.20 0.64 1.84 0.71 0.18
4.12 1.21 3.67 1.76 0.48
87 18 71 22 0.062
110 24 97 29 0.20
74 17 50 16 0.001
103 21 99 22 0.68
19 5 20 6 0.67
13 3 12 5 0.82
28 8 30 11 0.73
1,457 467 1,333 784 0.63
fter implantation.Im
3,
7
ft; CPR
etermition
re
59
46
3
IABP a
 pulmonary arterial pressure; PCWP  pulmonary capillary wedge pressure; RAP  right atrial
M
S
a
c
a
a
0
r
p
w
d
w
I
g
D
T
t
w
C
t
p
C
w
m
t
I
T
e
c
a
e
(
s
p
p
a
e
l
w
h
d
t
s
u
t
a
d
d
l
h
S
s
e
1587JACC Vol. 52, No. 19, 2008 Seyfarth et al.
November 4, 2008:1584–8 LVAD Versus IABP in Cardiogenic ShockWe measured multiple organ dysfunction scores, using
ODS and SOFA criteria. After 30 days, MODS and
Figure 1 Time Course of CPI Serum Lactate, and Hemolysis
(A) Time course of the modified cardiac power index (CPI) after implantation of
Impella LP2.5 or intra-aortic balloon pump. For Impella patients, total CPI is
shown as the sum of CPI attributable to the work of the left ventricle (LV) (CPILV;
red bars) and of the device (CPIImpella, black bars). (B) Time course of serum lac-
tate (mean  SD). (C) Time course of free hemoglobin (median and interquartile
range). *p  0.05 between treatment groups at the specific time points.OFA scores had improved significantly in both treatment drms (Fig. 2A). In particular, after 30 days, median serum
reatinine level was 1.2 (1.0 to 2.0) mg/dl in patients
ssigned to Impella versus 0.8 (0.7 to 0.9) mg/dl in patients
ssigned to IABP (p  0.17), and serum bilirubin level was
.9 (0.4 to 1.2) mg/dl and 1.2 (1.0 to 1.5) mg/dl (Impella,
espectively IABP; p  0.35). In the Impella group, 6
atients survived without neurological deficit compared
ith 4 patients in the IABP group. At discharge echocar-
iographically determined left ventricular ejection fraction
as 35  17% in the Impella group versus 45  17% in the
ABP group (p  0.34). Overall, 6 patients died in each
roup within 30 days (Fig. 2B).
iscussion
his study is the first randomized clinical trial to evaluate
he feasibility, safety, and efficacy of a new LVAD compared
ith the IABP in patients with CS caused by AMI.
ompared with other LVADs, the catheter-based, minia-
urized rotary blood pump Impella LP2.5 affords easy
ercutaneous access (2). The use of Impella LP2.5 increased
I, cardiac output, and MAP 30 min after implantation,
hereas IABP significantly reduced DAP. The improve-
ent in hemodynamics with the Impella device may explain
he more rapid reversal of serum lactate levels observed in
mpella patients, although this did not reach significance.
he use of positive inotropic drugs or vasopressors was
xpected to be lower in patients with Impella. However, we
ould not detect any differences in the overall use of these
gents. Calculation of the CPI was additionally used to
stimate the hemodynamic support offered by the LVAD
7). The endogenous cardiac work of Impella patients was
ignificantly lower than in patients with IABP at all time
oints. This may explain why the overall cardiac output of
atients with Impella was not a simple sum of pump flow
nd endogenous cardiac output. Furthermore, this may
xplain why a significant hemodynamic improvement was
imited to the first hours after implantation.
Complex organ dysfunction scores (MODS and SOFA)
ere used to evaluate overall outcome. Reversal of the
emodynamic derangement resulted in better scores at 30
ays in both groups without a significant difference between
reatment arms. Explanation for the overall lack of a
ignificant improvement in clinical outcome may be attrib-
table to the protocol used, which left it to the discretion of
he physician how long the mechanical device was used,
fter the primary end point was reached.
We also investigated the feasibility and safety of the new
evice in patients with CS. There was no technical failure
uring support and no increase in major bleeding, distal
imb ischemia, arrhythmias, or infection. The increase in
emolysis in Impella patients was only transitory.
tudy limitations. A major limitation of the study is the
mall number of patients, which did not allow for a meaningful
valuation of potential mortality differences. Therefore, evi-
ence from this initial study can only serve as support for future
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LVAD Versus IABP in Cardiogenic Shock November 4, 2008:1584–8arger studies to test for a clinical benefit or mortality reduction.
nother limitation may be the early time point chosen for
rimary end point assessment, which was intended to avoid the
oss of patients by early mortality. This obviously impedes the
xtrapolation of the present results to the effects of longer
emodynamic support by Impella. Finally, the Impella LP2.5
s the smallest LVAD with the advantage of a percutaneous
pproach, albeit limited by the maximal pump flow of 2.5
/min. Therefore, future studies might evaluate not just the best
hoice of initial device, but also the optimal time point to
witch to a higher-output but more invasive device in
atients with CS (2,8).
onclusions
his randomized study shows the feasibility and safety of a
ercutaneously delivered LVAD implanted in patients with
S caused by AMI. The LVAD Impella LP2.5 offered an
ffective and superior hemodynamic support in these pa-
ients compared with standard treatment using IABP coun-
erpulsation.
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APPENDIX
or details of the inclusion and exclusion criteria of the study, please seeFigure 2 Organ Dysfunction Scores and Survival Curve
(A) Multiple Organ Dysfunction Score (MODS). (B) Sepsis-related Organ Failure
Assessment (SOFA). Scores are shown at baseline and 30 days. Values are
mean  SD. *p  0.01 between baseline and 30 days for each score and
each treatment group. (C) Overall 30-day survival curves for Impella patients
versus intra-aortic balloon pump patients.he online version of this article.
